Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BTB domain-containing protein 1 (BTBD1) is a protein encoded by the BTBD1 gene in humans. The protein features a BTB/POZ domain, typically involved in protein-protein interactions, particularly through its N-terminus which also has a proline-rich region. The C-terminus can bind topoisomerase I (TOP1). BTBD1 is believed to function as a probable substrate-specific adapter in an E3 ubiquitin-protein ligase complex, promoting the ubiquitination and proteasomal degradation of target proteins[1][2][8]. It may be involved in regulating the expression or subnuclear distribution of TOP1 and plays a potential role in mesenchymal cell differentiation, promoting myogenic differentiation and suppressing adipogenesis[2][8]. While it has been linked to rare pediatric cancers such as congenital mesoblastic nephroma and childhood fibrosarcoma, it is not a classical therapeutic target (such as a receptor, enzyme, transporter, or channel)[2]. There are currently no known drugs targeting BTBD1 directly, and its biomarker and safety relevance are unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BTB domain-containing protein 1 (BTBD1).